S&P Futures
3,853.75+8.75(+0.23%)Dow Futures
31,153.00+57.00(+0.18%)Nasdaq Futures
13,347.50+53.25(+0.40%)
Oramed Pharmaceuticals Inc. (ORMP)
4.2800 -0.03 (-0.70%)
Before hours: 7:22AM EST
Chart Events
Performance Outlook
| Previous Close | 4.4400 |
| Open | 4.3800 |
| Bid | 4.2400 x 1200 |
| Ask | 4.2800 x 800 |
| Day's Range | 4.2350 - 4.4100 |
| 52 Week Range | 2.4000 - 5.5800 |
| Volume | 230,220 |
| Avg. Volume | 559,340 |
| Market Cap | 114.909M |
| Beta (5Y Monthly) | 1.98 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6580 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.60 |
- Simply Wall St.
We're Hopeful That Oramed Pharmaceuticals (NASDAQ:ORMP) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- PR Newswire
Oramed to Present at H.C. Wainwright BioConnect 2021 Conference
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that CEO Nadav Kidron will present a company overview at the H.C. Wainwright BioConnect 2021 Conference, held virtually from January 11-14, 2021. The presentation will be available on demand to conference participants as of January 11.
- PR Newswire
Oramed Reports Positive First in Human Data from Oral Leptin Study
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today results from a proof-of-concept study approved by Israel's Ministry of Health for its oral leptin drug candidate. The single dose study evaluated oral leptin's safety and pharmacodynamics (glucagon and glucose reduction) in type 1 diabetic (T1DM) patients.
